Lobello et al. performed a next-generation sequencing analysis of 82 patients with ALCL (including 47 ALK + and 35 ALK-negative patients); the authors reported that TP53 mutation occurred in 23% of ALK-negative ALCL cases and 11% of ALK + ALCL cases and correlated with inferior outcome [14]. The gene discussed is TP53; the disease is anaplastic large cell lymphoma.